IL2RA and acute lymphoblastic leukemia: An ongoing phase I study of patients with relapsed/refractory CD25-positive AML/ALL treated with the human monoclonal anti-CD25 antibody ADCT-301 (NCT02588092) showed an acceptable safety profile.